Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.
about
Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.Reply to 'Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers'.
P2860
Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Efficacy and Safety of Switchi ...... nts with Rheumatoid Arthritis.
@en
type
label
Efficacy and Safety of Switchi ...... nts with Rheumatoid Arthritis.
@en
prefLabel
Efficacy and Safety of Switchi ...... nts with Rheumatoid Arthritis.
@en
P2093
P2860
P50
P1433
P1476
Efficacy and Safety of Switchi ...... ents with Rheumatoid Arthritis
@en
P2093
Dae Hyun Yoo
Eun Young Lee
Francisco Fidencio Cons Molina
Francisco G Medina-Rodriguez
Jung-Yoon Choe
Leysan Myasoutova
Marina Stanislav
Mie Jin Lim
Pawel Hrycaj
Piotr Wiland
P2860
P2888
P304
P356
10.1007/S40259-017-0233-6
P577
2017-08-01T00:00:00Z